Member Info for Hurst10

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.

https://www.ft.com/content/6f12dad4-dc09-4bb5-b1c7-941eb2408bac

Shares in Sanofi fell 15 per cent on Friday after the French pharmaceutical group announced a lower profit outlook and a spinout of its consumer care unit as it seeks to focus investment in drug research.

Sanofi’s shares down 20%, however this another company who have expressed strong interest in precision medicine!

140-5 before US opening.

Size buyer wants stock NOW

Size buyer back, using BEGO.

Wants to be best bid, NY coffee team back

Size buyers moving in, watch out for a lively Friday.

A new report from Tufts Medical Center’s New Drug Development Paradigms (NEWDIGS) program shows that cell and gene therapies for orphan diseases and hematological cancers are two to 3.5 times more likely to be successful than other types of treatments for similar conditions, or as compared to the entire drug pipeline.

CAR-T/TCR therapies for blood cancers were three times more likely to be approved when entering phase 1 compared to the average oncology drug and over two times more likely than the average hematological oncology drug, it concluded.

Listening to Novartis yesterday making it very clear that Radiotherapy was one of their key growth areas, in Avacta’s case, the majors only have one problem:

Who goes first ?

However with AVA6000 and AVA3996,Cohort and the rest of the AVA family- Nasdaq could be round the corner sooner rather than later!

NY will be up early and size buyers will step it up a gear.

Watch out for Dr. Tap seen shaking hands with the FDA, two weeks works!!

Size prints post hours.

Novartis lifts 2023 earnings forecast for third time

Size buyers back in town!

Novartis beating numbers and upgrade.

Oct 24, 2023 - Third quarter & Nine months 2023 results

Basel, Switzerland

Watch the webcast

14:00 CEST | 13:00 BST | 08:00 EDT

Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary

The Swiss pharmaceutical company has agreed to buy Telavant, a company set up by Roivant and Pfizer to develop a promising inflammatory bowel disease treatment.

Eli Lilly presented at ESMO this week end.

Worth keeping an eye on their website.

Apologise ,computer playing up.

Conclusion is a counter bid for PointBiopharma.

More news from ESMO

Avacta news flow stepping up

Eli Lilly have already made 6 transactions this year, but market believes it will not stop them talking to PointBiopharma.

Eli Lilly could also approach Avacta for them to assist in such conversations, because of Avacta’s jv’s with PointBiopharma.

More to come from ESMO no doubt.

Eli Lilly presenting at ESMO, meanwhile they are talking to Point Biopharma.

Novartis will be needing Avacta’s support to maintain Point Bio, interesting to see how they will do that.

Watch Monday AM

Some of those prints on other sites are being shown as buys.

Size prints post hours.

Did you all see this :

TOKYO, Oct 19 (Reuters) - Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm depending on the success of the cell-targeting therapies.